Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation
M Ujeyl, I Köster, H Wille, T Stammschulte… - European journal of …, 2018 - Springer
Purpose The pivotal trials for stroke prevention in non-valvular atrial fibrillation (NVAF)
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation
M Ujeyl, I Koester, H Wille… - Eur. J. Clin …, 2018 - kups.ub.uni-koeln.de
PurposeThe pivotal trials for stroke prevention in non-valvular atrial fibrillation (NVAF)
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation.
M Ujeyl, I Köster, H Wille… - … Journal of Clinical …, 2018 - search.ebscohost.com
Purpose: The pivotal trials for stroke prevention in non-valvular atrial fibrillation (NVAF)
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
[PDF][PDF] Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation
M Ujeyl, I Köster, H Wille, T Stammschulte… - European Journal of …, 2018 - researchgate.net
Purpose The pivotal trials for stroke prevention in non-valvular atrial fibrillation (NVAF)
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation
M Ujeyl, I Köster, H Wille… - … Journal of Clinical …, 2018 - search.proquest.com
Purpose The pivotal trials for stroke prevention in non-valvular atrial fibrillation (NVAF)
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation.
M Ujeyl, I Köster, H Wille, T Stammschulte… - European Journal of …, 2018 - europepmc.org
Purpose The pivotal trials for stroke prevention in non-valvular atrial fibrillation (NVAF)
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation
M Ujeyl, I Köster, H Wille… - … journal of clinical …, 2018 - pubmed.ncbi.nlm.nih.gov
Purpose The pivotal trials for stroke prevention in non-valvular atrial fibrillation (NVAF)
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation
M Ujeyl, I Koester, H Wille… - Eur. J. Clin …, 2018 - kups.ub.uni-koeln.de
PurposeThe pivotal trials for stroke prevention in non-valvular atrial fibrillation (NVAF)
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …